Antibody-Drug Conjugates: Possibilities and Challenges

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody Drug Conjugates (ADCs) leverage antibody targeting for precise delivery of cytotoxic payloads to tumor cells.
• Despite their potential, early ADCs faced significant limitations impacting clinical efficacy.

Purpose of the Study:

• To review the fundamental components of ADCs: tumor markers, antibodies, cytotoxic payloads, and linkage strategies.
• To highlight technical advancements and future directions in ADC development for improved cancer treatment.

Main Methods:

• Review of existing literature on Antibody Drug Conjugate design and clinical application.
• Analysis of key components and challenges associated with ADC therapies.

Main Results:

• ADCs combine antibody-mediated targeting with potent cytotoxic agents for cancer therapy.
• Numerous obstacles, including low efficacy, toxicity, and resistance, have impeded ADC clinical success.
• Ongoing research focuses on optimizing ADC components and overcoming these limitations.

Conclusions:

• The development of Antibody Drug Conjugates is crucial for advancing targeted cancer therapy.
• Addressing current challenges in ADC design is essential for achieving high-efficient clinical outcomes.
• Future trends indicate continued innovation in ADC technology for improved therapeutic potential.